Integrating New Technology into Blood Plasma Fractionation

Publication
Article
BioPharm InternationalBioPharm International-09-01-2002
Volume 15
Issue 9

by John Curling, ProMetic BioSciences Ltd. Immune serum globulin is in high demand, and that demand will only increase. Yet despite product shortages, the complexities involved in creating new manufacturing processes discourage change. The benefits - increased yield, reduced costs, new technologies, and faster throughput - now make identifying the best place in the processing stream to make manufacturing changes a rewrding endeavor. Planned change always trumps losing market share or being forced to change by new regulations.

Recent Videos
David Fairen-Jimenez
Industry Outlook 2025: The Rising Prominence of AI in Pharma
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.